As shown in Figure 7B, peripheral blood human CD45% in the vehicle-treated group increased every week to nearly 30% by week 4, indicating aggressive progression of disease (AML), while treatment with HSN748 and Gilteritinib showed a decline in the presence of peripheral blood human CD45-positive cells. Here, PTPRC is linked to acute myeloid leukemia.